公开(公告)号：WO2023039500A1

公开(公告)日：2023-03-16

申请号：PCT/US2022/076156

申请日：2022-09-09

Applicant: STATERA PHARMA INC.

Inventor： VERSI, Ebrahim ,  SIDDLE, Nicholas

IPC: A61K9/00 ,  A61K31/565 ,  A61K31/566 ,  A61K31/568 ,  A61K31/567 ,  A61K38/25 ,  A61P13/00 ,  A61P13/02 ,  A61P43/00

Abstract: The present invention relates to compositions and local delivery methods to increase pelvic tissue integrity and the treatment, reduction and/or prevention of stress urinary incontinence [SUI | and fecal incontinence [FI] due to weakness in pelvic floor. The treatment comprises of growth and/or repair promoting compound(s) [GRPCs] including but not limited to androgens, androgen receptor modulators, ghrelin, a ghrelin analog, an estrogen, an estrogen receptor modulator, or a combination thereof for delivery into the vagina, anorectal canal or through the mucosa in these viscera to treat pelvic floor disorders.

公开(公告)号：WO2022104413A1

公开(公告)日：2022-05-27

申请号：PCT/AU2021/051361

申请日：2021-11-17

Applicant: DAY, Bryce Nicholas

Inventor： DAY, Bryce Nicholas

IPC: A61K31/4155 ,  A61K31/277 ,  A61K31/568 ,  A61P15/00 ,  A61P5/28 ,  A61P21/06 ,  A61P5/26 ,  A61K31/5685

Abstract: Provided herein are compositions, methods and kits for effectively preventing, treating, reducing, mitigating, or controlling female sexual interest and arousal disorder (FSIAD), wherein the method comprises administering to a subject in need thereof (i) a non-steroidal anti-androgen drug having minimal blood-brain-barrier penetration in a dosage that completely or partially blocks peripheral androgen receptors; and (ii) a supra-physiological dose of an anabolic androgenic steroid (AAS), a pro-drug, precursor or pro-hormone of an AAS, or a selective androgen receptor modulator (SARM).

公开(公告)号：WO2020022659A1

公开(公告)日：2020-01-30

申请号：PCT/KR2019/007806

申请日：2019-06-27

Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.

Inventor： AHN, Byoung Ki ,  PARK, So Hyun

IPC: A61K9/00 ,  A61K47/44 ,  A61K47/06 ,  A61K31/568 ,  A61P5/24

Abstract: The present invention relates to an injectable composition of testosterone ester for the treatment of testosterone deficiency. Particularly, the present invention relates to a pharmaceutical composition comprising testosterone undecanoate, which is capable of increasing the convenience for use in injection with the low viscosity and injection force, and has improved stability.

公开(公告)号：WO2019241077A1

公开(公告)日：2019-12-19

申请号：PCT/US2019/036137

申请日：2019-06-07

Applicant: ABON PHARMACEUTICALS LLC.

Inventor： AHMED, Salah U. ,  ZU, Yanming ,  CHOWDHURY, Tahseen A. ,  MUNTAZIM, Saad ,  SYED, Mohammed Irfan

IPC: A61K31/565 ,  A61K31/568 ,  A61K47/10

Abstract: The present disclosure relates to an oral eliglustat transmucosal delivery system. More specifically, the present disclosure is related to an oral transmucosal dosage form comprising a non-disintegrating solid mass comprising (a) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (b) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons and ( c) not more than 70 mg eliglustat, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec share rate.

公开(公告)号：WO2019152854A1

公开(公告)日：2019-08-08

申请号：PCT/US2019/016373

申请日：2019-02-01

Applicant: AYTU BIOSCIENCE, INC. ,  ACERUS BIOPHARMA INC.

Inventor： WESTFIELD, Gerwin ,  ZWIERKO, Margaux ,  RAMASAMY, Ranjith ,  BRYSON, Nathan

IPC: A61K31/568 ,  A61M5/20 ,  A61M5/30

Abstract: Methods and systems for preventing or reducing side effects of testosterone replacement therapy (TRT) by administering a testosterone formulation multiple times per day are disclosed. The methods of the present invention enable men who cannot tolerate previous TRT regimens, e.g. because they wish to attempt to conceive or are at risk of developing cardiovascular side effects, to receive TRT treatment.

公开(公告)号：WO2019140087A1

公开(公告)日：2019-07-18

申请号：PCT/US2019/013047

申请日：2019-01-10

Applicant: CELISTA PHARMACEUTICALS LLC

Inventor： DANDIKER, Yogesh ,  PANCHAL, Maulik Kiritkumar

IPC: A61K31/4196 ,  A61K31/568 ,  A61K38/24

CPC classification number: A61K31/568 ,  A61K9/7015

Abstract: The invention relates to a sprayable liquid solution for the transdermal delivery of testosterone comprising testosterone, a penetration enhancer, and a film forming excipient, and to methods of treatment using this composition.

公开(公告)号：WO2019088010A1

公开(公告)日：2019-05-09

申请号：PCT/JP2018/040065

申请日：2018-10-29

Applicant: 帝國製薬株式会社

Inventor： 川上　智 ,  堀川　靖

IPC: A61K31/568 ,  A61K9/70 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/24 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P5/26 ,  A61P5/50 ,  A61P9/10 ,  A61P15/10 ,  A61P15/12 ,  A61P19/10 ,  A61P21/00 ,  A61P25/24 ,  A61P25/28

Abstract: 本発明は、テストステロンの皮膚透過性に優れ、かつ製剤の物性に優れたテストステロン含有経皮投与製剤を提供する。具体的には、本発明は、膏体中に、テストステロン；ポリアクリル酸またはその塩；増粘剤；架橋剤；プロピレングリコールを含む可塑剤；および乳酸エステル、を含む経皮投与製剤を提供する。

公开(公告)号：WO2018134372A1

公开(公告)日：2018-07-26

申请号：PCT/EP2018/051347

申请日：2018-01-19

Applicant: IMMUNE SYSTEM REGULATION HOLDING AB

Inventor： WINQVIST, Ola ,  LINDH, Emma ,  WALLIN, Robert ,  GREGORY, Matt ,  MOSS, Steven

IPC: A61K38/09 ,  A61K31/565 ,  A61K31/568 ,  A61K31/57 ,  A61P31/04

Abstract: The present invention provides a method of treating intracellular infections, in particular intracellular bacterial, fungal, and protozoal infections.

公开(公告)号：WO2018118197A1

公开(公告)日：2018-06-28

申请号：PCT/US2017/056685

申请日：2017-10-14

Applicant: POSTREL, Richard

Inventor： POSTREL, Richard

IPC: A23K20/116 ,  A61K31/352 ,  A61K31/568

CPC classification number: A61K31/352 ,  A23K20/116 ,  A23K20/184 ,  A61K31/357 ,  A61K31/568

Abstract: This invention provides compositions, systems and methods that improve and/or optimize the health and performance of animals, especially mammals including humans, canines, equines, felines, etc. Key aspects of the principle invention and its parts include the monitoring, management and modulation of the body's natural cannabinoid systems through its native mechanisms thereby optimizing its processes by supplementation with endogenously occurring components and/or by administering synthetic compounds. The invention selects from multiple available resources to modify and/or rebalance an individual system or it may be applied across interconnected systems. The encompassing system that is intricately involved in the operations and intensities, e.g., the balancing of most other systems of our bodies, relates to cannabinoid compounds and their receptors. The cannabinoid pathways can be coordinated in rebalancing multiple and various metabolic pathways.

公开(公告)号：WO2018118196A1

公开(公告)日：2018-06-28

申请号：PCT/US2017056682

申请日：2017-10-14

Applicant: POSTREL RICHARD

Inventor： POSTREL RICHARD

IPC: A61K31/568 ,  A61K9/20 ,  A61K38/22

CPC classification number: A61K9/0019 ,  A61K31/198 ,  A61K31/525 ,  A61K31/568 ,  A61K33/06 ,  A61K33/32 ,  A61K38/063 ,  A61K38/13 ,  A61K2300/00

Abstract: The disclosure provides compositions and methods for improving or optimizing the health and performance of aging mammals, especially canines. The invention features two approaches that may be used independently in concert for compensating for aging and breed specific, species specific or individual genetic make up. The invention features compensating for decreasing androgen hormone levels circulating in the blood as an animal ages and along with improving outcomes through balancing androgen levels optimizes mitochondrial energy metabolism.